ELI LILLY AND COMPANY Total Long-Term Debt
ELI LILLY AND COMPANY (LLY) had Total Long-Term Debt of $29.47 billion as of 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2025-02-19
- 2024-12-31: Long-term Debt $29.47B.
- 2023-12-31: Long-term Debt $19.10B.
- 2022-12-31: Long-term Debt $14.82B.
- 2021-12-31: Long-term Debt $16.74B.
| Period end | Long-term Debt |
|---|---|
| 2024-12-31 | $29.47B 10-K · filed 2025-02-19 |
| 2023-12-31 | $19.10B 10-K · filed 2025-02-19 |
| 2022-12-31 | $14.82B 10-K · filed 2024-02-21 |
| 2021-12-31 | $16.74B 10-K · filed 2023-02-22 |
| 2020-12-31 | $16.35B 10-K · filed 2022-02-23 |
| 2019-12-31 | $13.64B 10-K · filed 2021-02-17 |
| 2016-12-31 | $9.01B 10-K · filed 2017-02-21 |
| 2015-12-31 | $7.98B 10-K · filed 2017-02-21 |
| 2013-12-31 | $5.21B 10-K · filed 2014-02-19 |
| 2012-12-31 | $5.53B 10-K · filed 2014-02-19 |
| 2011-12-31 | $6.98B 10-K · filed 2013-02-21 |
| 2010-12-31 | $6.79B 10-K · filed 2012-02-24 |
| 2009-12-31 | $6.66B 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |